Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01574248 · ClinicalTrials.gov registry record · Phase 4
Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT01574248 is a Phase 4 study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 33 participants.
The verdict
NCT01574248, a Phase 4 study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
Individuals with heart disease or high blood pressure are often prescribed angiotensin converting enzyme (ACE) inhibitors to treat their disease. However, the use of ACE inhibitors can be associated with angioedema, a rare but life-threatening condition that causes swelling of the face and other body parts. This study will evaluate the effectiveness of the drug HOE-140 at decreasing symptoms of angioedema in people taking ACE inhibitors who develop the condition.
Interventions
- OTHER Placebo
- DRUG icatibant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2011-08 |
| Est. Completion | 2016-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01574248
The ClinicalTrials.gov registry entry for NCT01574248 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01574248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01574248 about?
NCT01574248 is a clinical study titled "Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema". Individuals with heart disease or high blood pressure are often prescribed angiotensin converting enzyme (ACE) inhibitors to treat their disease. However, the use of ACE inhibitors can be associated with angioedema, a rare but life-threatening condition that causes swelling of the face and other bod...
What is the current status of trial NCT01574248?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2011-08. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01574248?
The interventions under investigation include: Placebo (OTHER), icatibant (DRUG).
Who is sponsoring clinical trial NCT01574248?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.